Quince Therapeutics, Inc. (QNCX)
QNCX Stock Price Chart
Explore Quince Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze QNCX price movements and trends.
QNCX Company Profile
Discover essential business fundamentals and corporate details for Quince Therapeutics, Inc. (QNCX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 May 2019
Employees
36.00
Website
https://www.quincetx.comCEO
Dirk Thye
Description
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
QNCX Financial Timeline
Browse a chronological timeline of Quince Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$25.40.
Stock split effective on 30 Jun 2026
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 11 May 2026
EPS came in at -$11.80 surpassing the estimated -$26.00 by +54.62%.
Stock split effective on 13 Apr 2026
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Apr 2026
EPS came in at -$86.00 falling short of the estimated -$3.59 by -2.29k%.
Earnings released on 12 Nov 2025
EPS came in at -$5.00 falling short of the estimated -$4.30 by -16.28%.
Earnings released on 12 Aug 2025
EPS came in at -$3.40 surpassing the estimated -$5.60 by +39.29%.
Earnings released on 13 May 2025
EPS came in at -$3.40 surpassing the estimated -$4.80 by +29.17%.
Earnings released on 31 Mar 2025
EPS came in at -$3.80 matching the estimated -$3.80.
Earnings released on 13 Nov 2024
EPS came in at -$1.30 surpassing the estimated -$1.73 by +25.00%.
Earnings released on 13 Aug 2024
EPS came in at -$1.80 .
Earnings released on 13 May 2024
EPS came in at -$2.60 .
Earnings released on 11 Mar 2024
EPS came in at -$4.40 surpassing the estimated -$5.60 by +21.43%.
Earnings released on 14 Nov 2023
EPS came in at -$4.40 surpassing the estimated -$5.60 by +21.43%.
Earnings released on 3 Aug 2023
EPS came in at -$1.40 .
Earnings released on 15 May 2023
EPS came in at -$68.00 falling short of the estimated -$61.85 by -9.95%.
Earnings released on 15 Mar 2023
EPS came in at -$1.30 surpassing the estimated -$5.75 by +77.40%.
Earnings released on 9 Nov 2022
EPS came in at -$4.40 surpassing the estimated -$5.60 by +21.43%.
Earnings released on 9 Aug 2022
EPS came in at -$10.20 falling short of the estimated -$7.40 by -37.84%.
Earnings released on 10 May 2022
EPS came in at -$14.40 falling short of the estimated -$11.00 by -30.91%.
Earnings released on 1 Mar 2022
EPS came in at -$15.60 falling short of the estimated -$13.00 by -20.00%.
Earnings released on 11 Nov 2021
EPS came in at -$14.60 surpassing the estimated -$14.80 by +1.35%.
Earnings released on 9 Aug 2021
EPS came in at -$14.80 surpassing the estimated -$15.20 by +2.63%.
QNCX Stock Performance
Access detailed QNCX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
